Investigational drug · Phase 3
HR091506
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gout With Hyperuricemia in Adults.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "HR091506"
First trial start
2023
Dec 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HR091506", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gout With Hyperuricemia in Adults
Approved drugs for the same conditions: Gout
Largest trials
Live from ClinicalTrials.gov: studies naming "HR091506" as an intervention, largest first.
- Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in AdultsPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06139393 · 765 participants · Start Dec 14, 2023 · Primary completion Aug 18, 2025
Drug: HR091506 tablets + placebo of febuxostat tablets; febuxostat tablets + placebo of HR091506 tablets · For: Gout With Hyperuricemia in Adults
Sites: Beijing, China
- Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in AdultsPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06414837 · 434 participants (planned) · Start Jun 2024 · Primary completion Jun 2026
Drug: HR091506 tablets + placebo of febuxostat tablets; febuxostat tablets + placebo of HR091506 tablets · For: Gout With Hyperuricemia in Adults
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05347498 · 90 participants (planned) · Start Apr 30, 2022 · Primary completion Jul 31, 2022
Drug: HR091506 tablets + placebo of febuxostat tablets; febuxostat tablets + placebo of HR091506 tablets · For: Primary Gout With Hyperuricemia in Adults
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07076459 · 36 participants · Start Jul 10, 2025 · Primary completion Aug 18, 2025
Drug: HR091506 tablet · For: Health Volunteer
Sites: Cangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.